Wang Mengmeng, Wu Jing-Xiang, Chen Lei
State Key Laboratory of Membrane Biology, Beijing Key Laboratory of Cardiometabolic Molecular Medicine, College of Future Technology, Institute of Molecular Medicine, Peking University, Beijing, China.
Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, China.
Front Pharmacol. 2022 Jun 30;13:929684. doi: 10.3389/fphar.2022.929684. eCollection 2022.
Mitiglinide is a highly selective fast-acting anti-diabetic drug that induces insulin secretion by inhibiting pancreatic K channels. However, how mitiglinide binds K channels remains unknown. Here, we show the cryo-EM structure of the SUR1 subunit complexed with mitiglinide. The structure reveals that mitiglinide binds inside the common insulin secretagogue-binding site of SUR1, which is surrounded by TM7, TM8, TM16, and TM17. Mitiglinide locks SUR1 in the NBD-separated inward-facing conformation. The detailed structural analysis of the mitiglinide-binding site uncovers the molecular basis of its high selectivity.
米格列奈是一种高度选择性的速效抗糖尿病药物,通过抑制胰腺钾通道来诱导胰岛素分泌。然而,米格列奈如何结合钾通道仍不清楚。在此,我们展示了与米格列奈复合的SUR1亚基的冷冻电镜结构。该结构显示,米格列奈结合在SUR1常见的胰岛素促分泌剂结合位点内部,该位点被TM7、TM8、TM16和TM17包围。米格列奈将SUR1锁定在NBD分离的内向构象中。对米格列奈结合位点的详细结构分析揭示了其高选择性的分子基础。